NYXH Nyxoah

Publication relating to transparency notifications

Publication relating to transparency notifications

                

REGULATED INFORMATION

Publication relating to transparency notifications

Mont-Saint-Guibert (Belgium), September 5, 2025, 10:30 pm CET / 4:30 pm ET In accordance with article 14 of the Act of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) announces that it received a transparency notification as detailed below.

On September 4, 2025, Nyxoah received a transparency notification from Cochlear Limited and Cochlear Investments Pty Ltd following a passive crossing of a threshold. Based on the notification, Cochlear Investments Pty Ltd holds 5,631,319 voting rights, representing 14.999% of the total number of voting rights on August 29, 2025 (37,544,782).

The notification dated September 4, 2025 contains the following information:

  • Reason for the notification: passive crossing of a threshold
  • Notification by: a parent undertaking or a controlling person
  • Persons subject to the notification requirement:
    • Cochlear Limited (with address at 1 University Avenue, Macquarie University, NSW 2109, Australia)
    • Cochlear Investments Pty Ltd (with address at 1 University Avenue, Macquarie University, NSW 2109, Australia)
  • Date on which the threshold was crossed: August 29, 2025
  • Threshold that is crossed: 15%
  • Denominator: 37,544,782
  • Notified details:



A) Voting rightsPrevious notificationAfter the transaction
 # of voting rights# of voting rights% of voting rights
Holders of voting rights Linked to securitiesNot linked to the securitiesLinked to securitiesNot linked to the securities
Cochlear Limited0000.00%0.00%
Cochlear Investments Pty Ltd3,947,6175,631,319015.00%0.00%
Subtotal3,947,6175,631,319  15.00% 
 TOTAL5,631,319 015.00%0.00%
  • Full chain of controlled undertakings through which the holding is effectively held: Cochlear Investments Pty Ltd is a wholly owned subsidiary of Cochlear Limited, which is listed on the Australian Securities Exchange and has no controlling shareholder.
  • Additional information: This notification concerns a downward crossing of the 15% threshold following a passive decrease, whereby Cochlear Investments Pty Ltd’s holding in Nyxoah fell from 15.04% to 14.999% of the voting rights.

*

* *

Contact:

Nyxoah

John Landry, CFO



Attachment



EN
05/09/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Nyxoah

 PRESS RELEASE

Nyxoah Invests In Further Expanding Its Belgian Manufacturing Capacity...

Nyxoah Invests In Further Expanding Its Belgian Manufacturing Capacity To Support Its Worldwide Growth Nyxoah Invests In Further Expanding Its Belgian Manufacturing Capacity To Support Its Worldwide Growth Mont-Saint-Guibert, Belgium – January 21, 2026, 10:05 pm CET / 4:05 pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today announced an important investment in Belgium to further scale its manufacturing capacity to suppo...

 PRESS RELEASE

Nyxoah Investit Dans l'Expansion De Sa Capacité De Production En Belgi...

Nyxoah Investit Dans l'Expansion De Sa Capacité De Production En Belgique Afin De Soutenir Sa Croissance Mondiale Nyxoah Investit Dans l'Expansion De Sa Capacité De Production En Belgique Afin De Soutenir Sa Croissance Mondiale Mont-Saint-Guibert, Belgique – 21 janvier 2026, 22h05 CET / 16h05 ET – Nyxoah SA (Euronext Bruxelles/Nasdaq : NYXH) (« Nyxoah » ou la « Société ») une société de technologie médicale spécialisée dans le développement et la commercialisation de solutions innovantes pour le traitement de l'Apnée Obstructive du Sommeil (« AOS ») par neuromodulation, a annoncé aujourd'h...

Jamila El Bougrini ... (+2)
  • Jamila El Bougrini
  • Thibaut Voglimacci-Stephanopoli
 PRESS RELEASE

Nyxoah Announces Preliminary Results for the Fourth Quarter and Full Y...

Nyxoah Announces Preliminary Results for the Fourth Quarter and Full Year 2025 and Provides Revenue Guidance for the First Quarter of 2026 INSIDE INFORMATIONREGULATED INFORMATION Nyxoah Announces Preliminary Results for the Fourth Quarter and Full Year 2025 and Provides Revenue Guidance for the First Quarter of 2026 Strong Start in First Full Quarter of U.S. Commercialization Mont-Saint-Guibert, Belgium – January 12, 2026, 10:05 pm CET / 4:05 pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company that develops breakthrough treatment a...

 PRESS RELEASE

Nyxoah Annonce ses Résultats Préliminaires pour le Quatrième Trimestre...

Nyxoah Annonce ses Résultats Préliminaires pour le Quatrième Trimestre et l'Ensemble de l'Exercice 2025 et Communique des Prévisions de Chiffre d'Affaires pour le Premier Trimestre 2026 INFORMATIONS PRIVILÉGIÉESINFORMATIONS RÉGLEMENTÉES Nyxoah Annonce ses Résultats Préliminaires pour le Quatrième Trimestre et l'Ensemble de l'Exercice 2025 et Communique des Prévisions de Chiffre d'Affaires pour le Premier Trimestre 2026 Un Démarrage Solide pour le Premier Trimestre Complet de Commercialisation aux États-Unis Mont-Saint-Guibert, Belgique – 12 janvier 2026, 22h05 CET / 16h05 ET – Nyxoah SA ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch